^
Association details:
| Biomarker: | MYC overexpression |
|---|---|
| Cancer: | Mantle Cell Lymphoma |
| Drug: | edralbrutinib (TG-1701) (BTK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract 2205: TG-1701, a novel irreversible Bruton's kinase (BTK) inhibitor, cooperates with ublituximab-driven ADCC and ADCP in in vitro and in vivo models of ibrutinib-resistant mantle cell lymphoma
Published date:
05/15/2020
Excerpt:
In another set of cell-based assays, we showed that the treatment with TG-1701 led to a strong decrease in IL-10 expression, together with a significant increase in IL-2, IL-6 and IL1RN gene transcription, thus associating TG-1701 exposure with the promotion of an immune response within the tumor microenvironment (TME).
DOI:
10.1158/1538-7445.AM2020-2205
